Verrica Pharmaceuticals Inc.
VRCA
$5.16
-$0.07-1.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 101.19% | 52.08% | 34.18% | 7.83% | -56.38% |
| Total Depreciation and Amortization | -40.42% | -38.82% | 16.59% | 62.86% | 61.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -59.79% | -43.52% | -20.84% | -70.78% | 86.85% |
| Change in Net Operating Assets | -385.45% | -82.64% | -184.06% | 4,021.71% | -152.32% |
| Cash from Operations | 38.60% | 36.45% | -10.73% | 42.22% | -250.35% |
| Capital Expenditure | -- | -- | 100.00% | 75.38% | 81.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 103.52% | 75.38% | 81.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2,247.46% | -2,500.64% | -1,526.09% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 5,500.00% | -195.08% | -629.76% |
| Cash from Financing | -549.22% | -513.77% | 146,122.22% | -100.90% | -661.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.52% | 18.80% | 258.32% | -130.76% | -253.47% |